We have isolated a Xenupus homolog of the murine Max-2 gene. As is the case for the mouse homolog, mesoderm specific expression of Xenopus Mox-2 (X. MOX-2) expression begins during gastrulation. Using whole mount in situ hybridization, we show that X. MOX-2 is expressed in undifferentiated dorsal, lateral and ventral mesoderm in the posterior of neurula/tailbud embryos, with expression more anteriorly detected in the dermatomes. In the tailbud tadpole, X. Mox-2 is expressed in tissues of the tailbud itself that represent a site of continued gastrulation-like processes resulting in mesoderm formation. X. Max-2 is not expressed in the marginal zone of blastula, nor in the dorsal lip of gastrula, nor midline tissues (i.e. prospective notochord). Treatments that affect mesodermal patterning during embryonic development, including LiCl and ultraviolet light, and injection of mRNAs encoding BMP4, or dominant negative activin and FGF receptors, produce changes in X. Max-2 expression consistent with the types of tissues affected by these manipulations. X. Mox-2 expression is induced more in animal caps treated with FGF than those treated with activin. Together with the fact that X. Mox-2 activation in animal caps requires protein synthesis, our data suggest that X. Mox-2 is involved in initial mesodermal differentiation, downstream of molecules affecting mesoderm induction and determination such as Brachyury and goosecoid, and upstream of factors controlling terminal differentiation such as MyoD and myf5. X. Mox-2, therefore, is another useful marker for understanding the formation of mesoderm in amphibian development.
Introduction
A working model for mesoderm induction in amphibians has been proposed whereby growth factors of the TGF-/I and FGF families released from the vegetal pole cells signal the overlying marginal ectoderm to induce mesoderm (reviewed in Slack, 1994) . Subsequently, factors including noggin (Smith et al., 1993) Wnts (Christian and Moon, 1993) , and BMP-4 (Dale et al., 1992; Jones et al., 1992; Graff et al., 1994; Harland, 1994) are involved in modifying these inductions, and further elaborating dorsoventral pattern. During gastrulation, a series of complex morphogenetic movements leading to interactions of the three germ layers results in the establishment of the primary anteroposterior axis, neural induction by planar and vertical signaling from the mesoderm, and region specific determination and differentiation (Gilbert and Saxen, 1993) .
Cell autonomous transcriptional regulators such as Xbru (Smith et al. 1991; Cunliffe and Smith, 1992) , goosecoid (Cho et al., 1991) , Xnot-2 (Gont et al. 1993) , Xlim-1 (Taira et al., 1992) , Pintdavis (Ruiz i Altaba and Jessell, 1992) and XFKHl (Dirsen and Jamrich, 1992) are all implicated in initially defining the mesoderm spatially and/or morphologically during gastrulation. Temporally, these genes are some of the earliest markers of pregastrulating presumptive mesoderm, and gastrulating mesoderm, and are thought to control downstream genes leading to differentiation of specific mesodermal tissues.
In order to understand processes such as gastrulation and mesodermal patterning it is useful to use the complementary advantages of two vertebrate model systemsin mice, genetic analysis, and in frog, direct experimental manipulation and biochemical analysis. We have previously presented the cloning and characterization of two 0925.4773/95/$09.50 0 1995 Elsevier Science Ireland Ltd. All rights reserved SSDf 0925-4773(95)00384-D A. F. Candia, C. V. E. Wright I Mechanisms of Development 52 (1995) [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] related mesoderm-specific murine genes encoding presumed homeodomain-containing transcription factors, Mox-I and Mox-2 (Candia et al., 1992) . To complement our ongoing genetic analysis of these genes, we have isolated a Xenopus homolog of the murine, mesoderm/mesenchyme-specific homeobox gene Max-2. The expression pattern of Xenopus Mox-2 (X. Max-2) is very similar to that of mouse Mox-2, being expressed first in presomitic mesoderm that has just undergone gastrulation. In addition, we have analyzed the regulation of X. Mox-2 expression in embryos in which patterning has been perturbed, and in animal caps treated with mesoderm inducing factors. Our data indicate that X. Mox-2 functions downstream of early mesodermal determinants such as Xbra, Xlim-I and goosecoid, and that X. Mox-2 provides another useful marker for mesoderm after its induction and before overt differentiation.
Results

I. Isolation of Xenopus Mox-2
A reverse-transcriptase PCR (RT-PCR) strategy was 1An;GAAcAcAcAcTATI?GGcTrxcnTr-;cpGcmcA'I6o MEHTLFGCLRSPHATSQGLH used to isolate a Xenopus cDNA fragment encoding a homeodomain sequence identical to that of mouse Mox-2. This fragment was used to screen a stage 17 neurula cDNA library, yielding a partial 1 kb cDNA encoding a protein with high amino acid sequence identity (86%) to mouse Mox-2. The coding sequence was completed from cDNAs extended at the 5' end and from genomic sequences (see Candia et al., 1993) . From the level of sequence identity (Fig. l) , and the data presented below, the cDNA appears to represent the Xenopus homolog of mouse Mox-2. In this manuscript, for brevity and clarity, we have designated this gene X. Mox-2.
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After numerous low stringency library screenings (cDNA and genomic), and degenerate RT-PCR attempts, we have not been able to isolate a Xenopus homolog of mouse Mox-1. We did isolate a Xenopus cDNA related to CHox-7 (Fainsod and Gruenbaum, 1989 ) that has a limited similarity (69%) to the Mox homeodomain in the region where our primers were designed, suggesting that our PCR strategy should have been able to isolate all Mox related genes. Although not formal proof, the simplest interpretation of these combined data is that Xenopus has only one Mox gene, most related to murine Mox-2. Consistent with this suggestion is the observation by Futreal et al. (1994) who failed to detect Mox-I in lower vertebrates (chicken) on multi-species genomic Southern blots.
Expression of Mox-2 during Xenopus development 2.2.1. RNase protection analysis.
To determine a spatiotemporal profile of X. Mox-2 steady-state transcript levels, RNase protection assays were carried out. Taking advantage of the ability to collect synchronously developing embryos at closely spaced time intervals, we determined the time of X. Mox-2 activation precisely in relation to the process of mesoderm induction and gastrulation. Fig. 2A shows that X. Mox-2 mRNA is not detected before mid-blastula transition (MBT), indicating that stable X. Mox-2 transcripts are not stored maternally. X. Max-2 mRNA is first detected at low levels in stage lO-10.25 embryos (initial gastrula stage; Nieuwkoop and Faber, 1967) . Steady state levels of X. Mox-2 mRNA increase during gastrulation and neurulation, reaching maximal levels in early tailbud (stage 21), after which overall levels of X. Mox-2 mRNA per embryo start to decrease (data not shown). The onset of X. Mox-2 &anscription post-gastrulation suggests that X. Mox-2 is not an immediately early response gene involved in mesoderm induction. This is substantiated by animal cap assays presented below.
An approximate spatial profile of X. Mox-2 mRNA was determined by RNase protection of RNA from embryos dissected into thirds along the anteroposterior axis. As Fig. 2B shows, X. Mox-2 was not found in the anterior third of stage 21 and stage 24 embryos but was found predominantly in the trunk and tail. These RNase protec- tion data presented are consistent with the in situ pattern of expression for X. Mox-2 presented below.
2.2.2. In situ analysis. To obtain a detailed spatial expression profile for X. Mox-2, whole mount in situ hybridization analyses were carried out. We could not detect any signal specific for X. Mox-2 at stages corresponding to the first time RNA was detected by RNase protection (st 10.29, presumably because of sensitivity limitations of the whole mount technique. The first time at which X.Mox-2 signal could be localized was at midgastrulation (stage 11). At this stage, X. Mox-2 transcripts are found in a crescent around the yolk plug in ventral mesoderm, lateral mesoderm, and in the dorsal paraxial mesoderm that later becomes the somites (Fig. 3A,3B ). X. Mox-2 is not detected in the mesoderm of the dorsal midline or the immediate, post-involution mesoderm cir-cumscribing the yolk plug ( Fig. 3A,B ). Sections of whole mount in situ embryos (such as those in Fig. 4A ,B) confirm that X. Mox-2 RNA is found in the involuted dorsolateral mesoderm, and transiently in the ventral mesoderm. X. Mox-2 is not expressed in the most anterior mesoderm, or mesoderm adjacent to the yolk plug that is in the process of, or just completing, involution (Fig. 3A) .
We also compared the expression pattern of X. Mox-2 in relation to that of the pan-mesodermal marker Xbra in whole embryos (Fig. 3C ). Xbra expression at midgastrula is observed circumblastoporally in the involuting and newly involuted mesoderm, while X. Mox-2 mRNA is detected in an interiorly located crescent of involuted mesoderm immediately anterior to the Xbra expression (compare Fig. 3A ,B to Fig. 3C ). Additionally, in contrast to Xbra, X. Mox-2 is not present in dorsal midline tissues, the site of future notochord formation ( Fig. 3A,B,D) .
At neurula and early tailbud stages, X. Mox-2 is expressed in the posterior of the embryo in paraxial and ventrolateral mesoderm (Figs. 3D, 4C,D). A gradient of X. Mox-2 expression within the prospective myotomal mesoderm is apparent in parasagittal sections, and in more anterior regions of the same embryos, where somite segmentation and differentiation is occurring, X. Mox-2 signal becomes restricted to the forming dermatomes (Figs. 3D and 4C) . At late tailbud stages ( Fig. 3E ), X. Mox-2 RNA is obvious only in the extending tailbud although, after extended color development, a lower level of X. Mox-2 is also detected in mid-trunk dermatome (not shown). Transverse sections through tailbud stage embryos reveal that X. Mox-2 expression is absent from the prospective mesoderm in the chordoneural hinge (see Fig.  4D ). The expression of X. Mox-2 in the newly formed mesoderm of the tailbud is consistent with its expression in post-involution mesoderm earlier at gastrulation. In summary, X. Mox-2 expression is restricted to the mesoderm of early Xenopus embryos and is not detected in neural or endodermal tissues. X. Mox-2 is expressed in the newly involuted ventrolateral mesoderm and presomitic tissue at gastrulation.
During neurulation and early tailbud stages, X. Mox-2 RNA is detected in presomitic and undifferentiated mesoderm, and in the dermatomes, but is absent from the segmented myotomes. X. Mox-2 expression is not seen in head and cardiac mesoderm, nor in anterior ventral mesoderm at post gastrulation stages. At late tailbud stages (32-35), highest levels of X. Mox-2 mRNA are in newly formed mesoderm in the extending tail bud.
Manipulations that perturb development and pattern formation
As an initial attempt to understand the potential role of X. Mox-2 in development, the expression of X. Mox-2 was examined after treatments known to cause specific and reproducible gross alterations in pattern formation. Embryos exposed during cleavage stages to lithium undergo tb, Fig. 3 . In situ expression of X. Max-2 and comparison to Xbru. (A) and (B) Posterior and dorsolateral views, respectively, of X. Max-2 expression in a whole embryo at mid fo late gastrula (stage =11 and ~12, respectively). Expression of X. Max-2 is found in a crescent of ventral, lateral and dorsal mesoderm surrounding but not adjacent to the yolk plug (y). Expression is absent from the dorsal midline (e.g. notochord (no)). Anterior is away from the viewer. (C) Expression of Xbra at stage 12. Xbm is detected in the involuting and newly involuted mesoderm immediately surrounding the entire yolk plug (y) and in the notochord (no). Note that this embryo has not been cleared so that the deeper notochordal signal is masked by superficial tissues. Anterior is away from fhe viewer. (D) Dorsolateral view of a stage 17 embryo. The dermatomes (d) and undifferentiated posteriolateral mesoderm show expression of X. Max-2. (E) Lateral view of a late tailbud (stage 35) embryo. Highest expression is detected in the tailbud (tb). (F) and (G) Sense strand controls for stages 11 and 3.5, respectively. Anterior is to the left except where indicated. Abbreviations: n, neural tissue a dose dependent enhancement of dorsoanterior tissues (Kao and Elinson, 1988) . Embryos were treated at the 32-64 cell stage for various times with 0.3 M LiCI, collected at early and mid-tailbud stages (stages 21 and 24) and assayed for X. Mox-2 transcripts by RNase protection. As Fig. 5A shows, X. Max-2 expression decreases in embryos in which dorsoanterior tissues are enhanced at the expense of trunk and posterior tissues. In contrast, embryos exposed to ultraviolet irradiation fail to undergo cortical rotation and are deficient in Nieuwkoop center signaling, resulting in posterioventralized embryos. In this case, X. Max-2 expression increases as the relative contribution of posterioventral tissues increases (Fig. 5B) . In embryos injected with BMP-4 RNA, another ventralizing factor, the expression of X. Max-2 at neurula stage is reduced compared to sibling controls, and at later stages (tailbud) is almost completely abolished (Fig. 5C ). This may seem to contradict the results of UV irradiated embryos but, in these experiments, these two manipulations resulted in different embryonic phenotypes. The dorsoanterior indices (DAI; Kao and Elinson, 1988) of sibling embryos in the UV irradiation experiments showed that embryos were not completely ventralized, resulting in an enhancement of X. Max-2 expressing tissues (trunk-type) at the expense of anterior (head) structures. In contrast, the ventralized phenotype obtained in BMP-4 injected embryos is uniformly more severe, suppressing dorsal signaling and inhibiting gastrulation such that sibling embryos mostly have a DA1 of zero (Dale et al. 1992; Jones et al., 1992) . We conclude that, consistent with the current interpretation of BMP4 as a posterioventralizing Stg 24
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Efl-a --Efl -a factor, BMP-4 RNA injection causes a decrease in the posteriodorsal marker, X. Max-2, but an increase in the ventrolateral marker, Xhox-3 ( Fig. 5C ) (Dale et al. 1992; Jones et al., 1992) . X. Max-2 expression was also examined in embryos with patterning defects resulting from injection with mRNAs encoding dominant negative activin (AXAR) or FGF (XFD) receptors (Amaya et al., 1991 (Amaya et al., , 1993 Hemmati-Brivanlou and Melton, 1992) . Dominant negative activin receptor mRNA interferes with the formation of all mesoderm, while embryos injected with dominant negative FGF receptor mRNA are deficient specifically in posterior and ventral tissues. Fig. 5D correlates X. Mox-2 expression with the expected phenotypes we obtained using the dominant receptor molecules. X. Max-2 expression is severely inhibited in early embryos and is later eliminated by the presence of dominant negative FGF receptor. In contrast, the dominant negative activin receptor negatively affects the expression of X. Max-2 in neurula stage but not in tailbud stage embryos.
induction of X. Max-2 by activin or FGF in animal caps
To further address the regulation of X. Max-2 expression, in particular to place it with respect to mesoderm induction and primary patterning, the animal cap assay was used. Animal poles were explanted from stage 8 embryos and treated with either activin or basic FGF (bFGF) Fig, 5 . Expression of X. Max-2 in embryos after treatments that alter pattern formation.
(A) Dorsoanteriorized embryos. Embryos were treated at the 3244 cell stage with 0.3 M LiCl for various times resulting in grades of dorsoanterior indices (DAI) from 6 (3 min exposure) to 9 (7 min exposure). X. Max-2 RNA levels were assayed at stages 21 and 24. The lack of trunk and posterior tissues results in a loss of X. Max-2 expression.
(B) Posterioventralized embryos. Embryos were irradiated with 254 nm UV light 30-45 min post-fertilization resulting in the indicated DA1 indices. As embryos acquire more ventral trunk and posterior tissue X. MUX-~ expression increases. (C) Ventralization by injection of BMP-4 synthetic mRNA. Two different amounts of human BMP4 synthetic mRNA were injected at the one cell stage into the animal hemisphere.
L, low dose, 200 pg/embryo; H, high dose, 1 ng/embryo. X. Max-2 expression decreases in a dose-dependent manner. A Xhox-3 probe was used as a positive control and shows the expected increase in injected embryos at stage 15/16 (Jones et al., 1992) . The loading control (ODC) under the stage 15/16 X. Mox-2 protections is also the loading control for the Xhox-3 protections. The stage 15/16 RNase protections were carried with equal aliquots from the same RNA sample (approximately 5 embryo equivalents). (D) Embryos injected with mRNAs encoding dominant negative activin (AXAR) or FGF (XFD) receptors. 1.5-2 ng of synthetic mRNA was injected into each blastomere at the two cell stage. AXAR mRNA affects the levels of X. Mox-2 only at stage 16 and 19 while XFD mRNA affects the expression of X. Max-2 at all time assayed. The controls indicate that, in addition to the expected morphological phenotypes observed, AXAR and XFD mRNA affected expression of Xbra and cardiac actin, respectively. For the control RNase protections, the following embryo equivalent of RNA was used: Xbra, two; cardiac actin, one; and EFl-a. one. Embryos were taken for RNase protection analysis at the indicated times of development. 
FA
-FA -FA -FA-FA Fig. 6 . X. Max-2 expression is induced by the mesoderm inducing growth factors, activin and basic fibroblast growth factor (bFGF). (A) Animal caps explanted at stage 8 were treated with activin (20 @ml) or bFGF (50 @ml). They were allowed to develop to the indicated stages and ten caps from each treatment processed for RNase protection. Induction of X. Max-2 by activin did not occur until stage 11, approximately 4 h after exposure to growth factor. FGF induced the expression of X. Max-2 by stage 13. at concentrations which are known to induce primarily dorsal and ventral mesoderm, respectively. As Fig. 6 shows, X. Mox-2 is induced in animal caps treated with either activin or bFGF. However, activin signaling induces X. Mox-2 mRNA earlier than bFGF, while bFGF induces and maintains a higher level of X. Mox-2 expression, even out to early tailbud stages.
The temporal lag of X. Mox-2 induction in this assay and the in situ expression in whole embryos both suggest that X. Mox-2 expression is not an immediate early event of dorsal signaling or mesoderm induction. Additionally, inhibition of protein synthesis by treating animal caps with cycloheximide prevents X. Mox-2 expression, whereas the known immediate early mRNA, Xbru, is still induced (data not shown). These data are consistent with the hypothesis that X. Mox-2 expression is not an immediate early transcription event following mesoderm induction, but that it is involved in patterning or differentiation events subsequent to mesoderm involution.
Discussion
We have presented data describing a Xenopus homolog of the mouse mesoderm-specific homeobox gene Mox-2. Xenopus Mox-2 (X. Mox-2) was isolated using a degenerate homeobox-specific primer for first strand cDNA synthesis, and a Mox-specific primer for PCR. The conclusion that the two genes are truly homologs is supported not only by the sequence identity, but also by their expression patterns in normal and manipulated embryos.
X. Mox-2 expression begins at gastrulation in the interiorly-located, involuted mesoderm lying anterior of the prospective mesoderm surrounding the yolk plug. Postgastrulation, X. Mox-2 continues to be expressed in the newly determined, but as yet undifferentiated, mesoderm, and at lower levels in cells of the dermatome. At late tailbud stages, the latest time we have examined, the highest level of X. Mox-2 mRNA is in newly formed mesoderm, in tissues that are proposed by Gont et al. (1993) to arise as a result of continued gastrulation in this region of the embryo. Both murine and amphibian Mox gene expression begins during the later stages of gastrulation in determined, undifferentiated mesoderm. Because Mox genes are not expressed in the primitive streak of gastrulation stage mouse embryos, nor in the marginal zone or dorsal lip of frogs, they are probably not involved in mesoderm induction, but in the first steps of mesodermal differentiation. This hypothesis is substantiated by the comparison of embryonic expression patterns of Mox-2 and Brachyury ( Fig. 3 and 4 of this paper, and see Wilkinson et al., 1990; Candia et al., 1992) , and the requirement for protein synthesis to initiate X. Mox-2 transcription in animal caps treated with growth factors. The newly involuted mesoderm may receive initial determination cues provided by Brachyury and other spatially localized immediate early response genes such as goosecoid and Xlim-I. Following its involution, X. Mox-2 expression is established in a mesodermal domain clearly downstream, temporally and spatially, of these initial cues.
In murine somitic mesoderm, Max-2 expression is detected at 8.5-9.0 d.p.c. in the dermamyotome and sclerotome. After 9.5 d.p.c., Mox-2 RNA is found in the sclerotome, whereas it is absent from the myotome (Candia et al., 1992) . Although dermatomal expression of Mox-2 was difficult to see in our previous studies, we have recently used Mox-2 antibodies to immunolocalized Mox-2 in the dermatome (A. Candia and C. Wright; unpublished data) . The data presented in this manuscript indicates that the pattern of expression of Mox-2 in frog embryos essentially mirrors the mammalian expression pattern. It is expressed in paraxial presomitic mesoderm, becoming extinguished in the segmented myotome, and remaining at lower levels in the dermatome. We have not seen X. Mox-2 RNA attributable to sclerotomal expression. In Xenopus, the sclerotomal tissue is extremely sparse prior to metamorphosis (Hamilton, 1969) , although it existence has been inferred based on the expression of Xrwi (Hopwood et al., 1989) . It remains to be seen whether sclerotomal derivatives express higher levels of X. Mox-2 during metamorphosis, as they proliferate and undergo chondrogenesis to produce the skeleton. The changes in expression of X. Mox-2 in embryos with enhanced dorsoanterior (Fig. 5A) or posterioventral (Fig. 5B) tissues are dependent upon the types of mesodermal tissue present in embryos after these treatments. In embryos completely ventralized by BMP-4 RNA injection (Dale et al., 1992; Jones et al., 1992) X. Max-2 expression was reduced in a dose-dependent manner. We cannot explain why there is a low level of X. Max-2 RNA in neurula stage BMP-4 loaded embryos. However, BMP-4 does not exert its full ventralizing action until after gastrulation begins (CVEW and CM. Jones, unpublished data), Thus, a signal (perhaps from organizer tissue or its derivatives), which could be responsible for initiating X. Mox-2 expression in unmanipulated embryos, may act transiently before its attenuation by BMP-4.
Mesodermal expression of X. Max-2 was also affected in embryos injected with mRNAs encoding dominant negative activin (AXAR) or FGF (XFD) receptors (Amaya et al., 1991 (Amaya et al., , 1993 Hemmati-Brivanlou and Melton, 1992) . Injection of XFD affected the expression of X. Mox-2 at all times, while AXAR-injected embryos had similar levels of X. Max-2 RNA when compared to uninjetted controls at later stages (stage 24, Fig. 5D ). Since XFD injected embryos are deficient in posterior and trunk tissues, the lack of X. Mox-2 mRNA in these embryos is probably due to the absence of X. Mox-2 expressing mesoderm. In contrast, the equivalent expression of X. Mox-2 at the tailbud stage in uninjected and AXAR injected embryos suggests that, in our hands, the reduction of activin-like signaling at early stages did not prevent all mechanisms for X. Mox-2 activation from occurring, albeit later than in uninjected embryos. This is supported by the detection of a low level of Xbru by RNase protection in stage 11 AXAR-injected embryos (Fig. 5D ). In animal cap assays, both activin and bFGF induce X. Mox-2 expression. The lower level of X. Mox-2 mRNA elicited in activin-treated caps compared to FGF reflects the induction of a lower proportion of X. Mox-2 expressing tissue, and a greater fraction of more dorsal tissues (muscle and notochord), that do not express X. Mox-2. This was confirmed by an activin dose-response RNase protection in which higher levels of X. Mox-2 RNA were detected with lower concentrations (2-5 ng/ml) of activin when compared to the similar concentration used for the time course in Fig. 6 (20 ng/ml) (data not shown). In contrast, the higher level of X. Mox-2 induced by bFGF relative to activin correlates with the higher percentage of the animal cap diverted to X. Mox-2 expressing (ventrolateral) tissue.
In keeping with a role of Mox genes in a step downstream of mesoderm induction, animal caps isolated from embryos injected with murine Mox-I or Max-2, or X. Mox-2 synthetic mRNAs do not form mesoderm by morphological or molecular criteria (data not shown). In the whole embryo, ectopic expression of Mox gene products by injection of synthetic mRNAs into different blastomeres does not perturb normal Xenopus development (data not shown). These data suggest that Mox genes are not sufficient to alter the fate of tissues, and that they require other cofactors or activation of additional signaling pathways to carry out their function.
There are overlapping patterns of expression between X. Mox-2 and those reported for Xsna (Essex et al., 1993) , Xtwi (Hopwood et al., 1989) , XmyoD (Hopwood et al., 1992) and Xmyf-5 (Hopwood et al., 1991) suggesting that all of these factors, and probably others, are needed for proper mesodermal determination and differentiation. Because X. Mox-2 is not expressed in the newly involuted and determined mesoderm, nor in terminally differentiated mesodermal tissues, we suggest that it is involved in processes between these phases of mesoderm development, in the initial steps of differentiation. Degenerate oligonucleotide primers specific for both murine Max-l and Mox-2 were used in a standard reverse-transcriptase polymerase chain reaction (RT-PCR) assay to obtain a partial homeobox-specific cDNA. Briefly, poly-A+ selected mRNA from stage 16 (neurula) Xenopus embryos was incubated with a 1024-fold degenerate oligonucleotide that recognizes the third helix of most homeoboxes, and reverse transcribed according to the supplier (Pharmacia). The first strand cDNAs were added to a PCR reaction containing 5' and 3' Mox specific oligonucleotides and Taq polymerase, and cycled for 35 rounds. Appropriately sized fragments, analyzed by agarose electrophoresis, were isolated, subcloned and sequenced. The amino acid sequence encoded by several subclones was identical to the murine Mox-2 homeodomain. The PCR fragment was used to screen a Xenopus stage 17 cDNA library at high stringency. A partial 1 kb cDNA was isolated that encoded an amino acid sequence with 86% identity to murine Mox-2 homeodomain.
Experimental procedures
I. Isolation of Xenopus
The coding region was completed by isolating appropriate genomic sequences from a Xenopus genomic library.
Xenopus embryos, tissue explants and manipulations
Eggs from hormonally stimulated Xenopus laevis fe-males were fertilized in vitro using testis homogenates. Embryos were dejellied in 2% cysteine (pH 7.9) and staged according to Nieuwkoop and Faber (1967) . Animal caps explants were isolated at stage 8, treated overnight with indicated factors in 0.75X normal amphibian medium (NAM, 1 X NAM = 110 mM NaCl, 2 mM KCl, 1 mM Ca(NO&, 1 mM MgS04, 0.1 mM EDTA, 2 mM NaP04, pH 7.5, 1 mM NaHCOs) and transferred to fresh 0.75~ NAM for further culture. To inhibit protein synthesis, explants were pretreated with 1 pg/ml cycloheximide in 0.5X modified Barth's saline (MBS, 1 X = 88 mM NaCl, 1 mM KCl, 0.41 mM CaC12, 0.33 mM Ca (NO,), 0.82 mM MgS04, 2.4 mM NaHCO,, 10 mM HEPES, pH 7.4) for 30 min, and then transferred to dishes with growth factors in 0.5X MBS, with or without cycloheximide for 4-5 h and then collected for RNase protection.
Lithium treatment consisted of exposing embryos to 0.3 M LiCl at the 32-64 cell stage for various times and transferring them to 0.1 x MBS. Embryos treated with UV irradiation were exposed in a quartz dish for 20-35 s, 45 min post-fertilization.
Between stage 4 and 6, embryos were transferred to fresh 0.1 X MBS for continued development.
Injection of synthetic mRNAs was carried out with a Singer micromanipulator and a gas-driven injector (Narashige). Between 5 and 10 nl of liquid was delivered to each blastomere at the one or two cell stage, and amounts of RNA are indicated in the figure legends. Synthetic capped mRNAs were generated using a pSP64-X/3m vector system described by Krieg and Melton (1987) .
RNase protections
Total RNA was isolated from explants and whole embryos, and used in RNase protection analyses as described (Cho and De Robertis, 1990) . Unless otherwise noted, ten embryo or animal cap equivalents of RNA was used for each sample. All assays were performed at least twice on RNA from separate injection experiments. An ornithine decarboxylase probe was included with the X. Mox-2 RNase protections to determine RNA integrity and to control for loading differences. An EFl-a probe was used as a loading control for Xbra and cardiac actin RNase protections. The 223 base pair X. Mox-2 RNase protection probe was generated from the 5' terminus of a partial X. Mox-2 cDNA (nucleotides 117-340 in Fig. 1 ).
Whole mount in situ RNA analysis
Whole mount in situs were carried out according to Smith and Harland (1992) with minor modifications:
Hybridizations were carried out between 60 and 65°C. RNase treatment was with Tl RNase alone. All immunoaffinity steps were carried out with Boehringer-Mannheim blocking reagent. Sense and antisense X. Mox-2 probes were generated from the original 1 kb X. Mox-2 cDNA and from the RNase protection probe. Both probes produced identical signal patterns. Sense control probes showed no specific signal above background at all stages examined. Section of whole mount in situ embryos were prepared by fixing in MEMFA (0.1 M MOPS, pH 7.4, 2 mM EGTA, 1 mM MgS04, 3.7% formaldehyde), dehydrating through ethanols, embedding in paraffin wax and sectioning at 16pm.
